Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC &gt;1 mg/L: A Multicenter Evaluation

Moise, Pamela A.; Culshaw, Darren; Wong-Beringer, Annie; Bensman, Joyce; Lamp, Kenneth C.; Smith, W. L.; Bauer, Karri A.; Goff, Debra A.; Adamson, Robert T.; Leuthner, Kimberly D.; Virata, Michael; McKinnell, James A.; Chaudhry, Saira; Eskandarian, Romic; Lodise, Thomas P.; Reyes, Katherine; Zervos, Marcus J.

doi:10.1016/j.clinthera.2015.09.017

Cited by 53 publications

(46 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is important because there is an association between high MICs within the susceptible range and adverse outcomes for patients with Gram-positive and Gram-negative bacterial infections. Regular surveillance of MICs is required due to a continuing decrease in susceptibility to the commonly used antibiotics in critically ill patients ( 50 – 52 ).…”

Section: Discussionmentioning

confidence: 99%

Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis

et al. 2018

View full text Add to dashboard Cite

We describe results from a multicenter study evaluating the Accelerate Pheno system, a first of its kind diagnostic system that rapidly identifies common bloodstream pathogens from positive blood cultures within 90 min and determines bacterial phenotypic antimicrobial susceptibility testing (AST) results within ∼7 h. A combination of fresh clinical and seeded blood cultures were tested, and results from the Accelerate Pheno system were compared to Vitek 2 results for identification (ID) and broth microdilution or disk diffusion for AST. The Accelerate Pheno system accurately identified 14 common bacterial pathogens and two Candida spp. with sensitivities ranging from 94.6 to 100%. Of fresh positive blood cultures, 89% received a monomicrobial call with a positive predictive value of 97.3%. Six common Gram-positive cocci were evaluated for ID. Five were tested against eight antibiotics, two resistance phenotypes (methicillin-resistant Staphylococcus aureus and Staphylococcus spp. [MRSA/MRS]), and inducible clindamycin resistance (MLSb). From the 4,142 AST results, the overall essential agreement (EA) and categorical agreement (CA) were 97.6% and 97.9%, respectively. Overall very major error (VME), major error (ME), and minor error (mE) rates were 1.0%, 0.7%, and 1.3%, respectively. Eight species of Gram-negative rods were evaluated against 15 antibiotics. From the 6,331 AST results, overall EA and CA were 95.4% and 94.3%, respectively. Overall VME, ME, and mE rates were 0.5%, 0.9%, and 4.8%, respectively. The Accelerate Pheno system has the unique ability to identify and provide phenotypic MIC and categorical AST results in a few hours directly from positive blood culture bottles and support accurate antimicrobial adjustment.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Table 1 summarizes studies that have assessed the incidence of nephrotoxicity following treatment with vancomycin or an alternative agent. In 2 of the 3 studies, vancomycin treatment was associated with a higher rate of nephrotoxicity and poorer clinical outcomes than alternative agents [38, 52]. Carreno et al [53], conducted a prospective randomized controlled trial to determine whether an early switch to an alternative therapy (daptomycin, linezolid, or ceftaroline) would prevent AKI in high-risk patients treated with vancomycin.…”

Section: Alternatives To Vancomycinmentioning

confidence: 99%

The Whole Price of Vancomycin: Toxicities, Troughs, and Time

Jeffres

2017

Drugs

143

View full text Add to dashboard Cite

Vancomycin is a glycopeptide antibiotic that is active against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. Nephrotoxicity, which is usually reversible, is the most serious common adverse effect of vancomycin. Vancomycin-associated nephrotoxicity prolongs hospital stays, imposes a need for additional antibiotics and, in rare circumstances, dialysis treatment, and increases medical costs and mortality. Risk factors for nephrotoxicity include the dose and duration of vancomycin treatment, serum trough concentration, patient characteristics, and concomitant receipt of nephrotoxins. Contemporary guidelines recommend targeting vancomycin trough concentrations of ≥10 mg/L to prevent resistance and trough concentrations of 15–20 mg/L to optimize outcomes. There is significant correlation between vancomycin trough serum concentrations and the incidence of vancomycin-associated nephrotoxicity; however, evidence of an association between trough concentrations and efficacy is less convincing. Routine monitoring of serum vancomycin concentrations consumes time and limited healthcare resources and may not be cost effective. The use of alternative antibacterial agents that do not require monitoring would free up pharmacy resources. This time could then be devoted to initiatives such as pharmacist-led antibiotic stewardship programs that are known to reduce antibiotic use and promote improved patient outcomes.

show abstract

“…However, prospective trials assessing the superiority of daptomycin over vancomycin in the setting of elevated MICs are in their infancy. A recent multicenter evaluation suggested no difference in composite failures between vancomycin and daptomycin, but higher rates of nephrotoxicity in patients receiving vancomycin …”

Section: Methicillin‐resistant Staphylococcus Aureusmentioning

confidence: 99%

“…A recent multicenter evaluation suggested no difference in composite failures between vancomycin and daptomycin, but higher rates of nephrotoxicity in patients receiving vancomycin. (26) Of increasing concern is the fact that resistance to both daptomycin and linezolid is being reported.…”

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

Multidrug‐resistant organisms in liver transplant: Mitigating risk and managing infections

Hand

Patel

2016

Liver Transpl

View full text Add to dashboard Cite

Liver transplant (LT) recipients are vulnerable to infections with multidrug-resistant (MDR) pathogens. Risk factors for colonization and infection with resistant bacteria are ubiquitous and unavoidable in transplantation. During the past decade, progress in transplantation and infection prevention has contributed to the decreased incidence of infections with methicillin-resistant Staphylococcus aureus. However, even in the face of potentially effective antibiotics, vancomycinresistant enterococci continue to plague LT. Gram-negative bacilli prove to be more problematic and are responsible for high rates of both morbidity and mortality. Despite the licensure of novel antibiotics, there is no universal agent available to safely and effectively treat infections with MDR gram-negative organisms. Currently, efforts dedicated toward prevention and treatment require involvement of multiple disciplines including transplant providers, specialists in infectious diseases and infection prevention, and researchers dedicated to the development of rapid diagnostics and safe and effective antibiotics with novel mechanisms of action.Liver Transplantation 22 1143-1153 2016 AASLD. Even with great improvements in infection prevention, surgical technique, and immunosuppression, bacterial infections remain responsible for poor outcomes in liver transplantation (LT). In an era of prolonged wait times, repeated and unavoidable exposures to both health care and antibiotics place LT candidates and recipients at high risk for both colonization and infection with multidrug-resistant organisms (MDROs).Multidrug resistance is frequently defined as bacteria resistant to at least 1 agent in at least 3 different antibiotic classes.(1) Despite this accepted definition, the definitions applied in studies describing MDROs are variable. MDRO colonization has been associated with subsequent infection and surgical complexities, requirement for immunosuppressive therapy, and necessary invasive interventions (eg, central venous catheters, urinary catheters, and mechanical ventilation) also add to the risk of MDRO infection in this susceptible population. In the absence of posttransplant complications, bacterial infections are more common early after LT.(2) Donor transmission of a MDRO has rarely been reported.Delays in effective empirical therapy, lack of experience with older and newer agents, and ever-changing susceptibility profiles in the setting of inadequate source control or selective antibiotic pressures contribute to the difficulties in treating patients infected with MDROs, specifically multidrug-resistant (MDR) gram-negative bacilli. In this review, we highlight risk factors and available treatment for some of the more common and problematic MDROs encountered in LT.

show abstract

Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation

Cited by 53 publications

References 22 publications

Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis

Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis

The Whole Price of Vancomycin: Toxicities, Troughs, and Time

Multidrug‐resistant organisms in liver transplant: Mitigating risk and managing infections

Contact Info

Product

Resources

About